What was studied?
This randomized, double-blind phase 3 trial assigned 1,210 adults with overweight or obesity and established type 2 diabetes to semaglutide study groups or placebo. Follow-up lasted 68 weeks and included lifestyle intervention.
What did the researchers report?
The primary comparison showed greater weight reduction with the investigated semaglutide formulation than placebo. The trial also examined the proportion reaching a prespecified weight-loss threshold and monitored adverse events.
What are the limits?
The result concerns adults with diabetes and specific baseline glucose-control criteria. It should not be treated as an independent estimate for people without diabetes or compared casually across trials. Study formulations and monitored treatment cannot be equated with catalog research materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.